Paul Kessler

Paul Kessler is a declared insider at 3 companies; the most frequent names are Prairie Operating Co., Research Solutions, Inc. and Iovance Biotherapeutics, Inc. We count 19 filings; the first trade dates from 1 November 2010 and the latest from 15 February 2017.

The open-market record is one-sided, with 14 purchases worth €2.6M and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants. In 2017 alone, the filings show 2 purchases and no sales.

In size, the median ticket on the buying side is €29k. None of the 4 purchases we analysed coincided with buying by another insider of the same company within 30 days. After 14 purchases with a full 90-day history, the hit rate stands at 29% and the median 90-day move at -16.9%. These figures describe past trades and do not predict future prices.

On 28 February 2017 came the latest disclosure, an open-market purchase for €1.2M in Prairie Operating Co. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.